C12N 2710/24141
Use of virus, viral particle or viral elements as a vector
C12N2710/24141 (Use of virus, viral particle or viral elements as a vector) appears on 674 US grants and 928 published applications in this corpus.
Search patents in C12N- Granted patents
- 674
- Published applications
- 928
- Assignees
- 403
- Inventors
- 1,378
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 9 | 0 |
| 1993 | 10 | 0 |
| 1994 | 5 | 0 |
| 1995 | 8 | 0 |
| 1996 | 10 | 0 |
| 1997 | 12 | 0 |
| 1998 | 34 | 0 |
| 1999 | 19 | 0 |
| 2000 | 14 | 0 |
| 2001 | 18 | 2 |
| 2002 | 13 | 10 |
| 2003 | 9 | 44 |
| 2004 | 18 | 33 |
| 2005 | 13 | 34 |
| 2006 | 26 | 43 |
| 2007 | 13 | 32 |
| 2008 | 18 | 33 |
| 2009 | 21 | 41 |
| 2010 | 18 | 46 |
| 2011 | 28 | 49 |
| 2012 | 28 | 46 |
| 2013 | 21 | 41 |
| 2014 | 28 | 21 |
| 2015 | 29 | 36 |
| 2016 | 15 | 24 |
| 2017 | 20 | 30 |
| 2018 | 23 | 28 |
| 2019 | 17 | 44 |
| 2020 | 24 | 48 |
| 2021 | 28 | 48 |
| 2022 | 21 | 57 |
| 2023 | 21 | 52 |
| 2024 | 26 | 33 |
| 2025 | 37 | 30 |
| 2026 | 13 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/24143Viral genome or elements thereof as genetic vectorIndexing code655
- C12N 2710/24142Virus or viral particle as vehicleIndexing code9
- C12N 2710/24144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code6
- C12N 2710/24145Special targeting system for viral vectorsIndexing code2
Recent patents
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers4 Aug 2026US 12,698,512 B2City of Hope
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Conditions improving poxvirus stability9 Jun 2026US 12,648,992 B2Bavarian Nordic A/S
- Rapid selection system for the generation of recombinant enveloped viruses8 Oct 2026US 2026/0308627 A1Probiogen AG
- Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof1 Oct 2026US 2026/0297196 A1Shanghai Sinobay Biotechnology Co., Ltd.
- Coronavirus vaccines inducing broad immunity against variants24 Sep 2026US 2026/0284179 A1Cambridge Enterprise Limited
- Monobodies selective to nras10 Sep 2026US 2026/0263609 A1New York University
- Methods of Isolating Poxviruses from Avian Cell Cultures27 Aug 2026US 2026/0248906 A1Bavarian Nordic A/S
Most cited
By later US patents
- Modified vaccinia virus298US 4,603,112 AHealth Research, Inc. · 1986
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Vaccinia DNA172US 5,017,487 AHoffmann-La Roche Inc. · 1991
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- Immunogenic composition comprising synthetically modified vaccinia virus144US 5,110,587 AHealth Research, Inc. · 1992